140 related articles for article (PubMed ID: 28847457)
21. Pharmacological interventions for drug-using offenders.
Perry AE; Neilson M; Martyn-St James M; Glanville JM; McCool R; Duffy S; Godfrey C; Hewitt C
Cochrane Database Syst Rev; 2013 Dec; (12):CD010862. PubMed ID: 24353217
[TBL] [Abstract][Full Text] [Related]
22. Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.
Gordon MS; Vocci FJ; Fitzgerald TT; O'Grady KE; O'Brien CP
Contemp Clin Trials; 2017 Feb; 53():130-136. PubMed ID: 28011389
[TBL] [Abstract][Full Text] [Related]
23. Extended-Release Naltrexone for Alcohol and Opioid Problems in Missouri Parolees and Probationers.
Crits-Christoph P; Lundy C; Stringer M; Gallop R; Gastfriend DR
J Subst Abuse Treat; 2015 Sep; 56():54-60. PubMed ID: 25841704
[TBL] [Abstract][Full Text] [Related]
24. Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry.
Saxon AJ; Akerman SC; Liu CC; Sullivan MA; Silverman BL; Vocci FJ
Addiction; 2018 Aug; 113(8):1477-1487. PubMed ID: 29493836
[TBL] [Abstract][Full Text] [Related]
25. Informed Assent Recall Among Adolescents in Substance Use Disorder Treatment Research.
Davis JP; Lux EA; Smith DC; Cleeland L
J Child Adolesc Subst Abuse; 2016; 25(5):417-427. PubMed ID: 27721646
[TBL] [Abstract][Full Text] [Related]
26. Antagonist Models for Relapse Prevention and Reducing HIV Risk.
Woody GE; Krupitsky E; Zvartau E
J Neuroimmune Pharmacol; 2016 Sep; 11(3):401-7. PubMed ID: 26922659
[TBL] [Abstract][Full Text] [Related]
27. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--chapter 7: Informed consent and xenotransplantation clinical trials.
Vanderpool HY
Xenotransplantation; 2009; 16(4):255-62. PubMed ID: 19799766
[TBL] [Abstract][Full Text] [Related]
28. [The origin of informed consent].
Mallardi V
Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
[TBL] [Abstract][Full Text] [Related]
29. Extended-release naltrexone and drug treatment courts: Policy and evidence for implementing an evidence-based treatment.
Robertson AG; Swartz MS
J Subst Abuse Treat; 2018 Feb; 85():101-104. PubMed ID: 28274648
[TBL] [Abstract][Full Text] [Related]
30. [An interim analysis of the results of treatment program implementation with the use of injectable extended-release naltrexone for opioid addicted patients].
Agibalova TV; Nedobylskiy OV; Poplevchenkov KN; Sirotko II; Shcherban AV; Tsarev SA
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):32-34. PubMed ID: 28745668
[TBL] [Abstract][Full Text] [Related]
31. [A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence].
Krupitsky EM; Blokhina EA; Zvartau EE; Verbitskaya VE; Bushara EM; Tiurina AA; Palatkin VY; Yaroslavtseva TS; Burakov AM; Masalov DV; Romanova TN; Grininko AY; Sinha R; Kosten T
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):39-46. PubMed ID: 26525620
[TBL] [Abstract][Full Text] [Related]
32. Comparing two methods for delivering clinical trial informed consent information to older adults: singular versus stepped approach.
O'Hare F; Flanagan Z; Nelson M; Curtis A; Heritier S; Spark S; Zoungas S
Clin Trials; 2018 Dec; 15(6):610-615. PubMed ID: 30074410
[TBL] [Abstract][Full Text] [Related]
33. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings.
Sinha R; Kimmerling A; Doebrick C; Kosten TR
Psychopharmacology (Berl); 2007 Mar; 190(4):569-74. PubMed ID: 17136399
[TBL] [Abstract][Full Text] [Related]
34. Lay public's understanding of equipoise and randomisation in randomised controlled trials.
Robinson EJ; Kerr CE; Stevens AJ; Lilford RJ; Braunholtz DA; Edwards SJ; Beck SR; Rowley MG
Health Technol Assess; 2005 Mar; 9(8):1-192, iii-iv. PubMed ID: 15763039
[TBL] [Abstract][Full Text] [Related]
35. Conducting Health Disparities Research with Criminal Justice Populations: Examining Research, Ethics, and Participation.
Valera P; Cook S; Macklin R; Chang Y
Ethics Behav; 2014 Mar; 24(2):164-174. PubMed ID: 25045243
[TBL] [Abstract][Full Text] [Related]
36. Assessing social risks prior to commencement of a clinical trial: due diligence or ethical inflation?
Burris S; Davis C
Am J Bioeth; 2009 Nov; 9(11):48-54. PubMed ID: 19882460
[TBL] [Abstract][Full Text] [Related]
37. "Teach-to-Goal" to Better Assess Informed Consent Comprehension among Incarcerated Clinical Research Participants.
Ahalt C; Sudore R; Bolano M; Metzger L; Darby AM; Williams B
AMA J Ethics; 2017 Sep; 19(9):862-872. PubMed ID: 28905727
[TBL] [Abstract][Full Text] [Related]
38. Process for obtaining informed consent: women's opinions.
Bento SF; Hardy E; Osis MJ
Dev World Bioeth; 2008 Dec; 8(3):197-206. PubMed ID: 19046257
[TBL] [Abstract][Full Text] [Related]
39. Narcotic antagonist treatment of the criminal justice patient-institutional vs outpatient-including a 24 hour detox naltrexone induction regimen with oral medication.
Brahen L; Wiechert V; Capone T
NIDA Res Monogr; 1976 Sep; (9):93-8. PubMed ID: 794727
[No Abstract] [Full Text] [Related]
40. Oral naltrexone maintenance treatment for opioid dependence.
Minozzi S; Amato L; Vecchi S; Davoli M; Kirchmayer U; Verster A
Cochrane Database Syst Rev; 2006 Jan; (1):CD001333. PubMed ID: 16437431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
